Chemical: Drug
trifluoperazine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for trifluoperazine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1415744 NC_000006.11:g.146022531T>C, NC_000006.12:g.145701395T>C, NG_012832.1:g.39461A>G, NM_001018041.1:c.302-15099A>G, NM_005670.3:c.302-15099A>G, XM_005267139.1:c.302-15099A>G, XM_006715564.2:c.302-15099A>G, XM_011536113.1:c.302-15099A>G, XM_011536114.1:c.302-15099A>G, XM_011536115.1:c.302-15099A>G, rs56685907
T > C
SNP
No VIP available CA VA
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Apo-Trifluoperazine
  • Eskazine
  • Eskazinyl
  • Fluoperazine
  • Jatroneural
  • Modalina
  • Novo-Trifluzine
  • PMS Trifluoperazine
  • Stelazine
  • Stelazine Concentrate
  • Stellazine
  • Synklor
  • Terfluzine
  • Trazine
  • Trifluoperazin
  • Trifluoperazina
  • Trifluoperazine Dihydrochloride
  • Trifluoperazine HCl
  • Trifluoperazine Hydrochloride
  • Trifluoromethylperazine
  • Trifluoroperazine
  • Trifluoroperazine Dihydrochloride
  • Trifluoroperazine Hydrochloride
  • Trifluperazine
  • Triflurin
  • Trifluroperizine
  • Triftazin
  • Triftazine
  • Triperazine
  • Triphtazin
  • Triphtazine
  • Triphthasine
  • Triphthazine
  • Triphthazine Dihydrochloride
  • Tryptazine
  • Tryptazine Dihydrochloride
Brand Mixture Names
  • Stelabid Forte (Isopropamide Iodide + Trifluoperazine Hydrochloride)
  • Stelabid No 1 (Isopropamide Iodide + Trifluoperazine Hydrochloride)
  • Stelabid No 2 (Isopropamide Iodide + Trifluoperazine Hydrochloride)

PharmGKB Accession Id

PA451771

Type(s):

Drug

Description

A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.

Source: Drug Bank

Indication

For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Source: Drug Bank

Pharmacology

Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Half-Life

10-20 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H24F3N3S

Source: Drug Bank

Isomeric SMILES

CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F

Source: OpenEye

Canonical SMILES

CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1

Source: Drug Bank

Average Molecular Weight

407.496

Source: Drug Bank

Monoisotopic Molecular Weight

407.164303088

Source: Drug Bank

SMILES

CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1

Source: Drug Bank

InChI String

InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank )
ATP4A (source: Drug Bank )
CALM3 (source: Drug Bank )
CALY (source: Drug Bank )
DRD2 (source: Drug Bank )
S100A4 (source: Drug Bank )
TNNC1 (source: Drug Bank )

Drug Interactions

Interaction Description
bromocriptine - trifluoperazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
bromocriptine - trifluoperazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
cisapride - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
dexfenfluramine - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
diethylpropion - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
donepezil - trifluoperazine Possible antagonism of action (source: Drug Bank )
donepezil - trifluoperazine Possible antagonism of action (source: Drug Bank )
fenfluramine - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
fenfluramine - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
galantamine - trifluoperazine Possible antagonism of action (source: Drug Bank )
galantamine - trifluoperazine Possible antagonism of action (source: Drug Bank )
gatifloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
gatifloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
guanethidine - trifluoperazine The agent decreases the effect of guanethidine (source: Drug Bank )
guanethidine - trifluoperazine Trifluoperazine may decrease the effect of guanethidine. (source: Drug Bank )
levofloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
levofloxacin - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
mazindol - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
mazindol - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
phentermine - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
phenylpropanolamine - trifluoperazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
tacrine - trifluoperazine The therapeutic effects of the central acetylcholinesterase inhibitor (ACEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. ACEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank )
tacrine - trifluoperazine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank )
terfenadine - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - trifluoperazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
tetrabenazine - trifluoperazine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. (source: Drug Bank )
thiabendazole - trifluoperazine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank )
trifluoperazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
trifluoperazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank )
trifluoperazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - donepezil Possible antagonism of action (source: Drug Bank )
trifluoperazine - donepezil Possible antagonism of action (source: Drug Bank )
trifluoperazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - galantamine Possible antagonism of action (source: Drug Bank )
trifluoperazine - galantamine Possible antagonism of action (source: Drug Bank )
trifluoperazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - guanethidine The agent decreases the effect of guanethidine (source: Drug Bank )
trifluoperazine - guanethidine Trifluoperazine may decrease the effect of guanethidine. (source: Drug Bank )
trifluoperazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - metrizamide Increased risk of convulsions (source: Drug Bank )
trifluoperazine - metrizamide Increased risk of convulsions (source: Drug Bank )
trifluoperazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank )
trifluoperazine - rivastigmine Possible antagonism of action (source: Drug Bank )
trifluoperazine - rivastigmine Possible antagonism of action (source: Drug Bank )
trifluoperazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trifluoperazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
trimethobenzamide - trifluoperazine Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )
triprolidine - trifluoperazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
triprolidine - trifluoperazine Triprolidine and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )
triprolidine - trifluoperazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
trospium - trifluoperazine Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to trifluoperazine: 5

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. Neuropsychobiology. 2016. Porcelli Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules (Basel, Switzerland). 2012. Ji Hye Young, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2007. Tay Joshua K X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical pharmacology and therapeutics. 2007. Yang S-Y, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0378-2401-01
DrugBank:
DB00831
PDB:
TFP
ChEBI:
45951
KEGG Compound:
C07168
PubChem Compound:
5566
PubChem Substance:
46507961
9377
IUPHAR Ligand:
214
Drugs Product Database (DPD):
776505
BindingDB:
50001886
ChemSpider:
5365
HET:
TFP
Therapeutic Targets Database:
DAP000034
FDA Drug Label at DailyMed:
c2575a86-19e5-44df-8603-ff066bb9c9c5

Clinical Trials

These are trials that mention trifluoperazine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.